Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lanabecestat on OC Pharmacokinetics in Healthy Females
NCT03506399Phase 1Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lanabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under The Concentration Curve of Ethinyl Estradiol at 120 hours, Area Under The Concentration Curve of Levonorgestrel at 120 hours and 2 more. Planned start Jun 2018; status: withdrawn.
02
Drugs
lanabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03506399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506399.